RGRX Stock Overview
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RegeneRx Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0014 |
| 52 Week High | US$8.80 |
| 52 Week Low | US$0.0002 |
| Beta | 2.62 |
| 1 Month Change | 16.67% |
| 3 Month Change | 16.67% |
| 1 Year Change | -99.97% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -97.3% | -4.2% | -3.7% |
| 1Y | -100.0% | -2.0% | 20.5% |
Return vs Industry: RGRX underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: RGRX underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| RGRX volatility | |
|---|---|
| RGRX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RGRX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RGRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 3 | J. Finkelstein | www.regenerx.com |
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics.
RegeneRx Biopharmaceuticals, Inc. Fundamentals Summary
| RGRX fundamental statistics | |
|---|---|
| Market cap | US$78.75k |
| Earnings (TTM) | -US$1.69m |
| Revenue (TTM) | US$76.76k |
0.0x
P/S Ratio0.0x
P/E RatioIs RGRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGRX income statement (TTM) | |
|---|---|
| Revenue | US$76.76k |
| Cost of Revenue | US$0 |
| Gross Profit | US$76.76k |
| Other Expenses | US$1.77m |
| Earnings | -US$1.69m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,199.83% |
| Debt/Equity Ratio | -38.2% |
How did RGRX perform over the long term?
See historical performance and comparison